Clinical trials: Prostate Cancer Aggressiveness
Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification, Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique
Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis
Objectives: To establish if there are differences between an ultrasound-guided transrectal prostate biopsy (BPTE) and a transperineal prostatic biopsy (BPTP) with and without a multiparametric Magnetic Resonance (RMmp) in…
- Conditions
- Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification, Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique, Establish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life, Establish the Association of the Tumor Biomarker in the Early Detection and Aggressiveness of Tumors
- Trial name
- RMPBX201801 (NCT04283032)
- Testing
- Multiparametric magnetic resonance
- Where
- Spain
- Volunteers
- 628 people
- Sponsor
- InvestigatorUrologyIBSAL
Malignant Solid Tumors, Primary Brain Tumor
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour…
- Conditions
- Malignant Solid Tumors, Primary Brain Tumor, Melanoma, Soft Tissue Sarcoma
- Trial name
- REGATA (NCT05539677)
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostate Cancer
CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr
To enable the paradigm of mp-MRI before biopsy in all patients with suspected prostate cancer by better selecting patients who will benefit from diagnostic MRI and by improving the performance of the mp-MRI itself
- Trial name
- INNOVATE (NCT02689271)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 365 people
- Sponsor
- University College, London
Prostate Cancer
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
- Trial name
- NCT06085729
- Testing
- ADI-PEG 20, Cabazitaxel, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
- Trial name
- NCT03256630
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Genomic Health®, Inc.
Prostate Cancer
Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients
The prostate gland is a clinically important male accessory sex gland and vital for its production of semen. Prostate cancer (PCa) is now ranked 3th in annual incidence of male cancer and ranked 5th for cancer-related death in…
- Trial name
- NCT03911999
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Prostate Hypoxia - TIC
Prostate cancer is the most commonly diagnosed form of cancer in Canadian men. In 2006, greater than 250,000 men were diagnosed with prostate cancer in the United States and Canada with more than 32,000 men dying of their…
- Trial name
- NCT02095249
- Testing
- Pimonidazole
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- uPAR-PET (NCT02437539)
- Testing
- Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cancer of the Prostate, Castration-resistant Prostate Cancer
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer
The purpose of this research study is to test to see if Gadoxetate Sodium is a useful contrast agent for detecting prostate cancer during magnetic resonance imaging (MRI).
- Trial name
- NCT03960788
- Testing
- Gadoxetate Sodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Cincinnati
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial
The Immune compleX Predictive Index (iXip) is a predictive tool for prostate cancer (PCa) diagnosis that integrates PSA, PSA-IgM, prostate volume and age of the patient.
- Trial name
- NCT03413007
- Testing
- Immune compleX Predictive Index
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate…
- Trial name
- CHAMP (NCT04709276)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer, Prostate Cancer Metastatic
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
In Europe, prostate cancer (PCa) is the second most frequent type of cancer in men and the fifth most lethal. Current clinical practices, often leading to overdiagnosis and overtreatment of indolent tumors, suffer from lack of…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent, Prostate Cancer Aggressiveness
- Trial name
- NCT05384002
- Testing
- Magnetic Resonance Imaging
- Where
- Italy
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model
A UCSF PI-initiated study with a primary goal to improve decision quality, anxiety, and uncertainty, thereby increasing appropriate uptake of active surveillance and reducing over-treatment of low-risk prostate cancer.
- Trial name
- NCT02451345
- Testing
- Personalized risk model+website+coaching intervention
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Francisco
Prostate Cancer (Adenocarcinoma), Prostate Cancer After a Radical Treatment
Genetic Studies of Prostate Cancer Aggressiveness and Prognosis
Prostate cancer is the most common form of cancer and the leading cause of cancer-related deaths among men in Sweden. In 2021, over 10,000 men were diagnosed with prostate cancer, and 2,077 died from the disease.
- Trial name
- NCT06773858
- Where
- Sweden
- Volunteers
- 2,291 people
- Sponsor
- Karolinska Institutet
Prostate Cancer Aggressiveness
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
- Trial name
- NCT04052048
- Testing
- Subtraction Normalized Expression of Phagocytes Blood Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Immunis.AI
Prostate Cancer
Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness
The purpose of this study is to develop, validate, and evaluate the correlation of novel magnetic resonance imaging (MRI) methods with prostate cancer aggressiveness and histological data obtained during prostatectomy.
- Trial name
- PROAG (NCT02545881)
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- NCT02139371
- Testing
- Injection of 64Cu-DOTA-AE105
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
In Europe, prostate cancer (PCa) is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer.
- Trial name
- NCT01672411
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Perugia